KURA ONCOLOGY, INC. Increase (Decrease) in Receivables
KURA ONCOLOGY, INC. (KURA) reported Increase (Decrease) in Receivables of $33.88 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2025-11-04
- KURA ONCOLOGY, INC. increase (decrease) in receivables for the quarter ending 2025-09-30 was $31.36M.
- KURA ONCOLOGY, INC. increase (decrease) in receivables for the quarter ending 2025-06-30 was -$44.17M.
- KURA ONCOLOGY, INC. increase (decrease) in receivables for the quarter ending 2025-03-31 was $46.69M.
| Period end | Increase (Decrease) in Receivables 3 month | Increase (Decrease) in Receivables 6 month | Increase (Decrease) in Receivables 9 month |
|---|---|---|---|
| 2025-09-30 | $31.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$12.81M derived: sum of 2 quarters · filed 2025-11-04 | $33.88M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$44.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.51M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $46.69M 10-Q · filed 2025-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |